Tyrphostin AG-556 reduces myocardial infarct size and improves cardiac performance in the rat

Experimental and Molecular Pathology

Volumn 74, Issue 3, 2003, Pages 314-318

  George, Jacob ^a   Biner, Simon ^a   Keren, Pnina ^a   Barshack, Iris ^b   Goldberg, Iris ^b   Sherez, Jack ^a   Levitzki, Alexander ^c   Keren, Gad ^a   Roth, Arie ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Inflammation; Myocardial infarct; Rat; Remodeling; TNF

Indexed keywords

N (4 BUTYLPHENYL) ALPHA CYANOCAFFEIC ACID AMIDE; TUMOR NECROSIS FACTOR ALPHA; TYRPHOSTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART; HEART INFARCTION SIZE; HEART PERFORMANCE; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SCAR FORMATION; SPLEEN CELL; SYSTOLE; TISSUE LEVEL;

EID: 0038392869     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4800(03)00022-4     Document Type: Article

References (16)

1. Bryant D., Becker L., Richardson J., et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis-alpha. Circulation. 97:1997;1375-1381.
2. Deswal A., Bozkurt B., Seta Y., et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure. Circulation. 99:1999;3224-3226.
3. Feldman A.M., Combes A., Wagner D., et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J. Am. Coll. Cardiol. 35:2000;537-544.
4. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines of the heart mediated by nitric oxide. Science. 257:1992;387-389.
5. Fuster V., Badimon L., Badimon J.J., et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Eng. J. Med. 326:1992;242-249.
6. Irwin M.W., Mak S., Mann D.L., et al. Tissue expression and immunolocalization of tumor necrosis factor-α in post infarction dysfunctional myocardium. Circulation. 99:1999;1492-1498.
7. Itoh G.J., Tamura M., Suzuki Y., et al. DNA fragmentation of human infarcted myocardial cells demonstrated by the nick and end labeling method and DNA agarose gel electrophoresis. Am. J. Pathol. 146:1995;1325-1331.
8. Lee J.K., Zidi S.H.E., Liu P., et al. A serine-elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally induced murine myocarditis. Nat. Med. 4:1998;1383-1391.
9. Li Y.Y., McTiernan C.F., Feldman A.M., et al. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc. Res. 42:1999;162-172.
10. Krown K.A., Page M.T., Nguyen C., et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes involvement of sphingolipid signaling cascade in cardiac cell death . J. Clin. Invest. 98:1996;2854-2865.
11. Novogrodsky A., Vanichkin A., Patya M., et al. Prevention of lipopolysaccharide induced lethal toxicity by tyrosine kinase inhibitors. Science. 264:1994;1319-1322.
12. Ono K., Mastsumori A., Shioi T., et al. Cytokine gene expression after myocardial infarction in rat hearts possible implication in left ventricular remodeling . Circulation. 98:1998;149-156.
13. Sevransky J.E., Shaked G., Novogrodsky A., et al. Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis. J. Clin. Invest. 99:1997;1966-1973.
14. St. John Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction. Circulation. 101:2000;2181-2188.
15. Vanichkin A., Patya M., Gazit A., et al. Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli induced lethal toxicity. J. Infect. Dis. 173:1996;927-933.
16. Vassalli P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:1992;411-451.